Biopharma specialist Averill Partners has launched Averill Madison, a new offshoot fund, according to an investor.
The new fund, which began trading in November, currently has $130 million under management. However, according to the investor, Madison is thought to be more scalable than the flagship product because it will predominantly emphasize large-cap stocks, while Averill Partners devotes roughly three-quarters of its capital to small- and mid-cap (SMID) stocks.
